You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC

Test Your Knowledge: Clinical Guidelines for the Management of Metastatic Castration-Resistant Prostate Cancer

  • Authors: Deborah Grainger, PhD; Tristin Abair, PhD
  • CME / ABIM MOC Released: 5/22/2023
  • Valid for credit through: 5/22/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematologists/oncologists, radiologists, urologists, and others involved in the care of patients with prostate cancer (excluding UK healthcare practitioners).

The goal of this activity is for the learner to be better able to discuss the evidence for the latest clinical guidelines surrounding treatment selection in mCRPC.

Upon completion of this activity, participants will:

  • Have greater competence related to
    • The latest clinical guidelines for treatment of mCRPC
  • Self-assess learning needs related to
    • Clinical characteristics that guide treatment selection in mCRPC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Deborah Grainger, PhD

    Medical Education Director
    WebMD Global, LLC

    Disclosures

    Deborah Grainger, PhD, has no relevant financial relationships.

  • Tristin Abair, PhD

    Senior Medical Writer
    WebMD Global, LLC

    Disclosures

    Tristin Abair, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25  AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Test Your Knowledge: Clinical Guidelines for the Management of Metastatic Castration-Resistant Prostate Cancer

Authors: Deborah Grainger, PhD; Tristin Abair, PhDFaculty and Disclosures

CME / ABIM MOC Released: 5/22/2023

Valid for credit through: 5/22/2024, 11:59 PM EST

processing....

References

  1. Mottet N, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6. EAU Guidelines Office, Arnhem, The Netherlands. http://uroweb.org/guidelines/compilations-of-all-guidelines/
  2. von Werdt A, et al. PARP inhibition in prostate cancer with homologous recombination repair alterations. JCO Precis Oncol. 2021;5:PO.21.00152.
  3. National Comprehensive Cancer Network Guidelines® (NCCN Guidelines®). Prostate cancer. Version 1.2023. Accessed April 26, 2023. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
  4. Zhang H, et al. PSMA theranostics: current landscape and future outlook. Cancers (Basel). 2021;13:4023. 
  5. Petrylak DP, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
  6. Berthold DR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242-245.
  7. Ryan CJ, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152-160.
  8. Armstrong AJ, et al. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer from the PREVAIL trial. Eur Urol. 2020;78:347-357.
  9. Lutetium (177Lu) vipivotide tetraxetan. European Medicines Agency EPAR product information. Approved September 2022. Updated April 19, 2023. https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf
  10. Sartor O, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091-1103.
  11. Hofman MS, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797-804. 
  12. Sadaghiani MS, et al. 177Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis. Prostate. 2022;82:826-835.
  13. Olaparib. European Medicines Agency EPAR product information. Approved November 2020. Updated March 24, 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza
  14. de Bono J, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091-2102.
  15. Hussain M, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383:2345-2357.
  16. Clarke NW, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evidence. Published online June 3, 2022. https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043
  17. Abida W, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020;38:3763-3772.
  18. Rucaparib [prescribing information]. Approved 2016. Revised May 2020.
  19. Smith MR, et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022;23:362-373.
  20. European Medicines Agency (EMA). Niraparib/abiraterone acetate. Accessed April 25, 2023. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/akeega#:~:text=The%20full%20indication%20is%3A,chemotherapy%
    20is%20not%20clinically%20indicate
  21. Chi KN, et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer [published online ahead of print, 2023 Mar 23]. J Clin Oncol. 2023;JCO2201649.
  22. de Wit R, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381:2506-2518.
  23. de Bono JS, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-1154.
« Return to: Test Your Knowledge: Clinical Guidelines for the Management of Metastatic Castration-Resistant Prostate Cancer
  • Print